Post Profile






Immunotherapy shows promising results in first, second line treatment of metastatic bladder cancer

Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials.
read more

share

Related Posts


New Drug For Advanced Colorectal Cancer Shows Promise In Trial

Health : Medical News Today

An experimental drug for advanced colorectal cancer that available approved treatments have failed to halt has shown promise in a clinical trial, says Bayer HealthCare, the company that makes it. The results of the phase III trial s...

Researchers evaluating immunotherapy approaches for treating metastatic kidney, prostate, bladder cancers

Health : Medical News Today

Researchers at the Roswell Park Cancer Institute (RPCI) Center for Immunotherapy are enrolling patients in three different clinical trials of novel immunotherapy approaches for treating genitourinary cancers. One of the studies will...

New Immunotherapy Approved for Metastatic Bladder Cancer

Health : Mayo Clinic News Blog

Patients with metastatic bladder cancer have few treatment options after failure of chemotherapy until now. In early May, the U.S. Food and Drug Administration (FDA) approved the immunological drug Atezolizumab to treat metastatic b...

Phase III Trial Results For 2nd Line Treatment Of Metastatic Colorectal Cancer To Be Presented At ESMO 13th World Congress On Gastrointestinal Cancer

Health : Medical News Today

Results of a large, multi-national phase III trial for second-line treatment of metastatic colorectal cancer will be presented for the first time at the ESMO 13th World Congress on Gastrointestinal Cancer, beginning June 22 2011 in ...

Immunotherapy: Promising results in first & second line treatment of metastatic bladder cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen.

Comments


Copyright © 2016 Regator, LLC